HC Wainwright Weighs in on Kiora Pharmaceuticals, Inc.’s Q1 2025 Earnings (NASDAQ:KPRX)

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRXFree Report) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Kiora Pharmaceuticals in a research note issued to investors on Monday, May 20th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Kiora Pharmaceuticals’ current full-year earnings is $0.11 per share. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

Kiora Pharmaceuticals Price Performance

Shares of Kiora Pharmaceuticals stock opened at $0.54 on Tuesday. The company’s fifty day moving average price is $0.56 and its two-hundred day moving average price is $0.58. Kiora Pharmaceuticals has a 52-week low of $0.45 and a 52-week high of $2.24.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Rosalind Advisors Inc. purchased a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRXFree Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,300,000 shares of the company’s stock, valued at approximately $1,624,000. Kiora Pharmaceuticals accounts for about 1.5% of Rosalind Advisors Inc.’s holdings, making the stock its 22nd biggest position. Rosalind Advisors Inc. owned 8.76% of Kiora Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

(Get Free Report)

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.

Read More

Earnings History and Estimates for Kiora Pharmaceuticals (NASDAQ:KPRX)

Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.